Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price […]